Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

– Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 – Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update